-
Dr Gopal on a Case Study of a Patient With Bladder Cancer
16 May 2024 23:23 GMT
… , according to Gopal. However, the bladder cancer treatment paradigm is expanding to include … . Conversely, the phase 3 AMBASSADOR trial (NCT03244384) evaluated pembrolizumab (Keytruda) vs …
-
Inside America’s critical shortage of drugs, from chemo to children’s medicine
17 May 2024 19:05 GMT
… Drug Administration in February shutting down the Intas Pharmaceuticals … appropriate alternatives, his treatment stopped. Jeff died … : the immunotherapy medication for his bladder cancer is in short … to fund alternative medications if the drugs they usually …
-
DN-1508052 by Shanghai De Novo Pharmatech for Oropharyngeal Cancer: Likelihood of Approval
17 May 2024 05:48 GMT
… of the drug, company and its clinical trials play a … under development for the treatment of solid tumors including … , cervical cancer, prostate cancer, bladder cancer, penile cancer, anal cancer, … on GlobalData’s Pharmaceutical Intelligence Center.
-
DN-1508052 by Shanghai De Novo Pharmatech for Hepatocellular Carcinoma: Likelihood of Approval
17 May 2024 05:48 GMT
… . Attributes of the drug, company and its clinical trials play a fundamental … is under development for the treatment of solid tumors including recurrent … cancer, cervical cancer, prostate cancer, bladder cancer, penile cancer, anal cancer, nasopharyngeal …
-
Paclitaxel by Fulgent Pharma for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
17 May 2024 04:27 GMT
… Attributes of the drug, company and its clinical trials play a fundamental … role in drug-specific PTSR … treatment of leukemia, gastric cancer, ovarian cancer and bladder cancer.
Fulgent Pharma overview
Fulgent Pharma …
-
PD-L1 Expression Associated With Favorable Tumor Features and Prognosis in Muscle-Invasive Bladder Carcinoma Without Immune CPI Treatment
15 May 2024 12:00 GMT
Photo Credit: Selvanegra
The following is a summary of “PD-L1 expression in tumor and inflammatory cells is associated with favorable tumor features and favorable prognosis in muscle-invasive urothelial carcinoma of the bladder not treated by immune …
-
Innate Pharma S.A. (NASDAQ:IPHA) Q1 2024 Earnings Call Transcript
15 May 2024 12:17 GMT
… the data with the FDA to define the next … tumor indication on top of bladder cancer by overcoming the challenges … monalizumab, Phase 2 clinical trials for the treatment of lung cancer. If … really characterize the pharmacodynamic effect of the drug in the T …
-
Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline
15 May 2024 10:55 GMT
… -risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in … 1/PD-L1 treatments. Transplant-related complications … keytruda_pi.pdf and Medication Guide for KEYTRUDA at … barriers to clinical trial participation, screening and treatment, we work …
-
OncLive’s April Roundup of Key FDA Decisions in Oncology
15 May 2024 06:56 GMT
… treatment of adult patients with BCG-unresponsive non–muscle-invasive bladder cancer … This is the third drug that is FDA approved in the past … the first drug to ever apply for FDA approval for … data, a phase 1 pharmacokinetic similarity trial, and a phase 3 …
-
TAR-200 Leads to Lasting Responses in BCG-Unresponsive Bladder Cancer
09 May 2024 14:00 GMT
… the phase 2 SunRISe-1 trial (NCT04640623) presented at the 2024 … were no treatment-related deaths.
In December 2023, the FDA granted breakthrough … for the treatment of high-risk non-muscle-invasive bladder cancer. News release …